AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Cytyc Corporation (CYTC) announced results for the first quarter ended March 31, 2004.
Revenues for the quarter rose 11% to $80.7 million compared to $72.6 million in the first quarter of 2003.
Net income for the first quarter of 2004 was $1.5 million, or $0.01 per diluted share, compared with $19.8 million, or $0.17 per diluted share, for the first quarter of 2003.
Excluding nonrecurring charges related to the acquisition of Novacept, net income was $20.6 million, or $0.18 per diluted share. Acquisition charges include acquired in-process research and development costs of $19.1 million.
"This has been an exciting first quarter and a great start to 2004," said Patrick J. Sullivan, Cytyc's chairman, chief ...
Source: HighBeam Research, Pap test developer reports 11% increase in revenues.